The result has given AZ an edge with Imfinzi over MSD's PD-1 inhibitor Keytruda (pembrolizumab), which failed to show an improvement in EFS in the KEYNOTE-585 trial, which looked at peri-operative use ...

Pharmaceutical organisations rarely struggle to write strategy. They struggle to protect it. Global brand teams define ambition precisely. Segmentation models are refined. Launch plans are ...

A study comparing outcomes after prostate cancer and breast cancer screening has shown that both are effective at diagnosing cases, reducing deaths, and avoiding unnecessary harm. The analysis – ...

In the 1,500-subject FIND-CKD study, the addition of Kerendia to standard treatment resulted in a reduction in the rate of kidney function decline, measured by tracking estimated glomerular filtration ...

Johnson & Johnson has revealed early clinical data with a new formulation of its FGFR inhibitor erdafitinib that suggests it could become the first targeted treatment for early‑stage bladder cancer.

The US regulator has cleared its Arexvy RSV shot for adults in that age group who are at increased ​risk of lower respiratory tract disease caused ​by the virus, having previously been cleared for the ...

This week saw both Regenxbio and Solid Bio report new data with their gene therapy candidates for Duchenne muscular dystrophy ...

Around half a million women in England will soon be able to access a non-hormonal treatment for hot flushes associated with ...

They are due to leave by the end of this year to set up an as-yet unnamed "independent biotechnology company to research and ...

Steve Sanghera is the CEO and co-founder of Inventus. With over 20 years of experience in technology and telecommunications, ...

In a second EU approval today, Johnson & Johnson got a green light for Akeega (niraparib and abiraterone acetate) for the ...

Interim results from RAINIER reveal that an 80 mg dose of povetacicept every four weeks delivered a 52% reduction in protein ...